From NANOmedicine to nanoMEDICINE: Converging Innovation for Clinical Adoption

nanomedicine INP

 
ABOUT THE ITALIAN NANOMEDICINE PLATFORM REGISTRATION & PAYMENTS DOWNLOAD DRAFT PROGRAMME in pdf (soon available)


ABOUT THE EVENT

A national milestone for nanomedicine in Italy

“From NANOmedicine to nanoMEDICINE: Converging Innovation for Clinical Adoption” is the first official symposium of the Italian Nanomedicine Platform, a new national initiative designed to connect technological innovation, clinical expertise, and industrial engagement around shared health priorities.

Over three days in Rome, the event will bring together researchers, clinicians, institutions, and industry to co-design the future of nanomedicine in Italy, with rare diseases and oncology as key model areas.

The symposium is co-organized with:

  • ETPN – European Technology Platform on Nanomedicine
  • MetabERN – European Reference Network for Hereditary Metabolic Disorders 

REGISTRATION & PAYMENT

  1. Registration (required)
    Before making any payment, please complete the registration form at this   LINK  

  2. Payment (after registration)
    Once you have registered, please proceed with the payment using one (or both) of the following links (after the registration):

DEADLINES

  • Pitch abstract submission deadline: 15 January 2026

  • Registration and payment deadline: 15 February 2026

OBJECTIVES

What we aim to achieve

This high-level symposium is designed to:

  • Officially launch the Italian Nanomedicine Platform and its Working Groups.
  • Build shared strategic priorities among clinicians, researchers, institutions, and companies.
  • Co-create and launch the first White Paper on Nanomedicine in Italy, with publication planned within 60 days after the event.
  • Promote institutional and political engagement, including collaboration with Farmindustria as strategic partner.
  • Test a new event format that favours dialogue, co-design, and real collaboration over traditional one-way presentations.
  • Empower a new generation of researchers able to bridge lab, clinic, and industry.

DRAFT PROGRAMME AT A GLANCE

calendario 16Day 1 – Monday, 16 February 2026 (Afternoon)
Kick-off & Platform Launch

  • Institutional opening and welcome
  • Presentation of Platform governance, vision, and Working Groups
  • Pitch Session: 20 × 3-minute pitches from labs, hospitals, and companies (who we are, what we bring, what we need)
  • “1-1-1 Wall”: each participant posts one need, one capability, one concrete ask
  • Working Group alignment on priorities for Day 2


calendario 17Day 2 – Tuesday, 17 February 2026 (Full day)
From Research to Reliable Products – From Clinic to Health Impact

Morning – Keynotes & Reverse Pitches

  • Keynote 1 – Diego Ardigò (Chiesi): PLUTO project in rare diseases
  • Keynote 2 – Raymond Schiffelers: mRNA-LNP and in vivo CAR-T for next-generation cancer immunotherapy
  • Clinician Reverse Pitch: what hospitals really need to use/develop nanomedicine (MetabERN and others)
  • Industry Reverse Pitch: how to reach the clinic and the market (e.g. Nanobiotix and other industry leaders)
  • Outputs: Clinician Go-Guide and Industry Go-Guide for the White Paper

Afternoon – Parallel Roundtables

  • Wave A – From Research to Reliable Products
    • Translating innovation: from concept to product definition
    • Scaling up smart: manufacturing, GMP, CMC, and industrial translation

  • Wave B – From Clinic to Health Impact
    • Clinical readiness in rare diseases
    • Evidence for adoption in oncology

Each table defines 3 concrete priorities (What · Owner · First step by 31 March 2026).


calendario 18Day 3 – Wednesday, 18 February 2026 (Morning)
Shaping the Future Together

  • Reports from focus groups (Top-3 priorities/actions per table)
  • Live ranking to select the Top-5 Actions for 2026
  • Plan and timeline for the Italian Nanomedicine White Paper
  • Platform governance and next steps, including a Q2 2026 “Rome Review” webinar
  • Closing remarks and European perspective

AUTHORITIES & PATRONAGES

Institutional authorities and stakeholders

Key national stakeholders invited to participate include:

  • Ministry of Health
  • AIFA – Italian Medicines Agency
  • Farmindustria, with the contribution of Dr. Enrico Piccinini, Coordinator of the Rare Diseases Group

Patronages (confirmed and invited)

  • SITELF – Italian Society of Pharmaceutical Technologists
  • MetabERN – European Reference Network for Hereditary Metabolic Disorders
  • Farmindustria
  • Patronages under invitation/confirmation: EVITA, CN3 PNRR, ETPN

WHO SHOULD ATTEND

This symposium is aimed at:

  • Researchers and PIs in nanomedicine, drug delivery, biomaterials, and advanced therapies
  • Clinicians and healthcare professionals interested in nanotechnology-based solutions
  • Representatives of pharmaceutical and biotech companies, SMEs, start-ups
  • Regulatory and policy experts (AIFA, EMA, ministries, agencies)
  • Patient representatives and networks, particularly in rare diseases and oncology
  • Early-career researchers, PhD candidates, and postdocs interested in translational paths